{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-048585","form_type":"8-K","ticker":"DMAA","cik":"0002028614","company_name":"Drugs Made In America Acquisition Corp.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.408477+00:00","generated_at":"2026-05-15T03:15:53.283532+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"DMAA updates CFO equity to 175k shares, sets CEO compensation terms, both tied to definitive deal","bullets":["CFO Saleem Elmasri's share grant increased from 100k to 175k ordinary shares, earned upon signing a definitive agreement and issued at closing of initial business combination.","CEO Roger Bendelac receives 250k ordinary shares under same vesting trigger; monthly cash comp of $4,500 with up to $2,000 deferrable based on cash flow.","Monthly CFO fee unchanged at $3,500; unpaid amounts accrue as binding obligations; shares replace prior unissued 100k.","Compensation structures signal progress toward a business combination, though no definitive agreement announced as of April 28, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-048585","json":"https://secwatch.observer/filing/0001213900-26-048585.json","markdown":"https://secwatch.observer/filing/0001213900-26-048585.md","text":"https://secwatch.observer/filing/0001213900-26-048585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026048585/0001213900-26-048585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026048585/ea0287918-8k_drugs.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:15:53.283532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}